Patents by Inventor Pasi A. Janne

Pasi A. Janne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF DIAGNOSING AND PROGNOSING LUNG CANCER
    Publication number: 20110119776
    Abstract: The present invention provides methods of detecting cancer using biomarkers.
    Type: Application
    Filed: February 4, 2008
    Publication date: May 19, 2011
    Inventors: Kwok-Kin Wong, Bruce Johnson, Pasi Janne, Hongbin Ji, Nabeel Bardeesy, Norman Sharpless
  • FISH ASSAY FOR EML4 AND ALK FUSION IN LUNG CANCER
    Publication number: 20110110923
    Abstract: Methods and compositions provided relate to conducting a FISH assay for detecting a chromosomal inversion between EML4 and ALK. The FISH assay described herein is useful for diagnostic and prognostic purposes, as well as for determination of therapeutic strategies.
    Type: Application
    Filed: February 12, 2009
    Publication date: May 12, 2011
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Charles Lee, Carly Murphy, Pasi Janne
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Publication number: 20080096212
    Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Application
    Filed: August 20, 2007
    Publication date: April 24, 2008
    Applicants: The General Hospital Corporation, Dana Farber Cancer Institute, Inc.
    Inventors: Daphne Bell, Daniel Haber, Pasi Janne, Bruce Johnson, Thomas Lynch, Matthew Meyerson, Juan Paez, William Sellers, Jeffrey Settleman, Raffaella Sordella
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Publication number: 20060147959
    Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Application
    Filed: December 5, 2005
    Publication date: July 6, 2006
    Applicants: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Daphne Bell, Daniel Haber, Pasi Janne, Bruce Johnson, Thomas Lynch, Matthew Meyerson, Juan Paez, William Sellers, Jeffrey Settleman, Raffaella Sordella